Menarini Ricerche to Sponsor Cancer Trial in Acute Myeloid Leukemia in USA
ROME, Aug. 6, 2018 /CNW/ - Menarini Ricerche, a company of the Menarini Group, announced today that the sponsorship of the ongoing Phase I/II study that is investigating MEN1703/SEL24 for the treatment of patients with relapsed/refractory (R/R) AML in the USA has been transferred from Selvita to Menarini Ricerche on June 30th 2018.
Selvita S.A. and Menarini Group entered into a global licensing agreement for SEL24/MEN1703 on March 28th, 2017. Menarini Ricerche has assumed full responsibility for clinical development activities after a period of very productive collaboration with Selvita. "We are delighted at the achievement of this very important milestone in our collaboration with Selvita. Together with our partners at Selvita, we look forward to progressing in the development of MEN1703/SEL24, and to expanding our knowledge of its potential to improve the lives of patients affected by AML," said Andrea Pellacani, M.D., Ph.D. (General Manager, Menarini Ricerche).
MEN1703/SEL24 is a first-in-class orally available dual PIM/FLT3 kinase inhibitor with a unique activity profile currently investigated for the treatment of AML and with preclinical data suggesting potential activity in other hematological malignancies and solid tumors.
Menarini Group is an Italian pharmaceutical company, 13th in Europe out of 5,345 companies, and 35th company in the world out of 21,587 companies, with a turnover of more than 3.6 billion Euro and 17,000 employees. The Menarini Group has always pursued two strategic objectives: research and internationalization, and has a strong commitment to oncology research and development. As part of such commitment to oncology, Menarini, is developing four investigational new oncological drugs. Two of them are biologics, namely the anti CD157 antibody MEN1112, and the toxin-conjugated, anti CD205 antibody MEN1309. In addition, Menarini has recently added two small molecules to its oncology pipeline, the dual PIM and FLT3 kinase inhibitor MEN1703, and the PI3K inhibitor MEN1611, in clinical development for the treatment of a variety of hematological and/or solid tumors. Menarini is active commercially in the most important therapeutic areas with products for cardiology, gastroenterology, pneumology, infectious diseases, diabetology, inflammation, and analgesia.
With 16 production sites and 7 Research and Development centers, the Menarini Group has a strong presence throughout Europe and Asia, Africa, Central and South America. Menarini's products are available in 136 countries worldwide.
For further information please visit http://www.menarini.com
Selvita S.A. is a clinical stage drug discovery company engaged in the research and development of novel cancer therapies, as well as provision of integrated drug discovery services. Selvita is headquartered in Krakow, Poland, with offices in the USA (Greater Boston, San Francisco Bay), and in the UK (Cambridge). Selvita has currently several projects at early or late discovery stage. Drug discovery clients of Selvita include numerous large and medium-sized pharmaceutical and biotechnology companies from USA and Europe. The company is listed on the Warsaw Stock Exchange (WSE:SLV).
For more information please visit https://selvita.com/
SOURCE Menarini Ricerche